High-Risk Renal Cell Carcinoma

NASHVILLE, Tenn. — Adjuvant pembrolizumab appeared well tolerated among patients with high-risk renal cell carcinoma after nephrectomy, according to study results.

Most patients with renal cell carcinoma ineligible for surgery and ablation achieved tumor reduction after treatment with nivolumab plus ipilimumab, according to study results.

Patients with mild to moderate chronic kidney disease or recipients of kidney transplants are at increased risk for cancer, according to data published in the American Journal of Kidney Disease.